In a groundbreaking move, the weight-loss injection Wegovy has recently been approved as a treatment for heart disease in the US. This comes after a major trial showed that the drug, also known as semaglutide, could reduce the risk of heart attack or stroke in people with obesity by a significant 20%.
With this approval, around 50,000 eligible individuals in the UK could potentially receive Wegovy through the NHS. Pharmaceutical company Novo Nordisk has already applied to the UK regulator for permission to provide the drug to more people with heart disease, expanding its reach even further.
Experts are now looking at Wegovy as a potential game-changer in the treatment of cardiovascular disease, comparing its potential impact to that of statins. The drug not only helps suppress appetite and promote weight loss but also boosts insulin production, offering potential heart benefits beyond just shedding pounds.
The decision from the UK regulator on expanding access to Wegovy is expected later this year, paving the way for more individuals to benefit from this innovative treatment. Stay tuned for further updates on this exciting development in the world of healthcare. Stay connected with Guam News Factor for more on this and other top stories.
“Zombie enthusiast. Subtly charming travel practitioner. Webaholic. Internet expert.”